BioCentury | Feb 28, 2020
Distillery Therapeutics

An antisense oligo inhibitor of miR-132 for heart failure

DISEASE CATEGORY: Cardiovascular INDICATION: Heart failure The miR-132 inhibitor CDR132L could treat heart failure. In pigs with post-myocardial infarction heart failure, CDR132L improved cardiac function, prevented end-systolic volume enlargement and reduced histologic evidence of interstitial...
BioCentury | May 2, 2018
Distillery Techniques

Chemistry; drug platforms

TECHNOLOGY: Tool compounds; structural analyses Structural analysis of a peptide inhibitor bound to the cysteine-rich domain (CRD) of FZD7 could guide the development of small molecule FZD7 inhibitors, and the peptide could be used to...
BioCentury | Mar 2, 2018
Clinical News

DBV reports Phase I/II data for milk protein allergy therapy

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) reported preliminary data from the Phase II portion of the Phase I/II MILES trial to treat IgE-mediated cow’s milk protein allergy showing that the once-daily 300 µg dose of Viaskin...
BioCentury | Nov 9, 2016
Clinical News

Viaskin Milk: Completed Ph I/II enrollment

DBV completed enrollment of about 176 patients ages 2-17 in the Phase II portion of the double-blind, placebo-controlled, North American Phase I/II MILES trial evaluating 150, 300 and 500 μg Viaskin Milk patch once daily...
BioCentury | Jul 11, 2016
Clinical News

Viaskin Peanut: Completed Phase III enrollment

DBV completed enrollment of >=350 patients ages 4-11 in the double-blind, placebo-controlled, international Phase III PEPITES trial evaluating 250 ug Viaskin Peanut for 12 months. DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT), Bagneux, France Product: Viaskin Peanut...
BioCentury | Dec 14, 2015
Clinical News

Viaskin Peanut: Phase III started

DBV began the double-blind, placebo-controlled, international Phase III PEPITES trial to evaluate 250 ug Viaskin Peanut for 12 months in about 330 patients ages 4-11. DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT), Bagneux, France Product: Viaskin Peanut...
BioCentury | Oct 26, 2015
Strategy

Collaborating on combos

As oncologists and drug developers converge on the idea that combination therapies built on a backbone of PD-L1 or PD-1 inhibitors could lead to cures for some cancers, or keep them at bay for years,...
BioCentury | Oct 26, 2015
Clinical News

Viaskin Peanut: Phase II data

Top-line data from the open-label, international Phase II OLFUS-VIPES trial in 171 patients showed that once-daily 250 ug Viaskin Peanut patches for 24 months led to a desensitization rate of 70%. OLFUS-VIPES enrolled patients who...
BioCentury | Apr 27, 2015
Company News

Curadev, Roche deal

Curadev and Roche partnered to develop inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase ( TDO2 ; TDO ) to treat cancer. The deal gives Roche exclusive, worldwide rights to develop and commercialize Curadev’s lead compound,...
BioCentury | Apr 21, 2015
Company News

Curadev, Roche partner to develop IDO1/TDO inhibitors for cancer

Curadev Pharma Pvt. Ltd. (New Delhi, India) and Roche (SIX:ROG; OTCQX:RHHBY) partnered to develop inhibitors of indoleamine 2,3-dioxygenase 1 ( IDO1 ) and tryptophan 2,3-dioxygenase ( TDO2 ; TDO ) to treat cancer. The deal gives Roche exclusive, worldwide...
Items per page:
1 - 10 of 26